The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment

@article{Nasreddine2005TheMC,
  title={The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment},
  author={Ziad Samir Nasreddine and Natalie A. Phillips and Val{\'e}rie B{\'e}dirian and Simon Charbonneau and Victor Whitehead and Isabelle Collin and Jeffrey L. Cummings and Howard Chertkow},
  journal={Journal of the American Geriatrics Society},
  year={2005},
  volume={53}
}
OBJECTIVES To develop a 10-minute cognitive screening tool (Montreal Cognitive Assessment, MoCA) to assist first-line physicians in detection of mild cognitive impairment (MCI), a clinical state that often progresses to dementia. [] Key MethodDESIGN Validation study. SETTING A community clinic and an academic center.

The Montreal Cognitive Assessment—Basic: A Screening Tool for Mild Cognitive Impairment in Illiterate and Low‐Educated Elderly Adults

To assess the validity of a newly developed cognitive screening tool, the Montreal Cognitive Assessment—Basic (MoCA‐B), in screening for mild cognitive impairment (MCI) in elderly adults with low

Montreal Cognitive Assessment and Mini–Mental State Examination are both valid cognitive tools in stroke

To determine the validity of the Montreal Cognitive Assessment (MoCA) and the Mini–Mental State Examination (MMSE) as screening tools for cognitive impairment after stroke.

Factor structure of the Montreal Cognitive Assessment in Parkinson disease

TLDR
The factor structure of the MoCA was tested in a large cohort of early Parkinson disease (PD) patients to provide evidence for various factor structures mapping to different cognitive domains.

Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment

TLDR
The aim of the present study is to examine the reliability and validity of the Brazilian version of the MoCA test (MoCA‐BR) in a sample of older individuals with at least 4 years of education.

Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington's disease

The Montreal Cognitive Assessment (MoCA) is a brief screening instrument for dementia that is sensitive to executive dysfunction. This study examined its usefulness for assessing cognitive

Brief screening tool for mild cognitive impairment in older Japanese: Validation of the Japanese version of the Montreal Cognitive Assessment

TLDR
The reliability and validity of the Japanese version of the MoCA (MoCA‐J), developed by Dr Nasreddine, is examined in older Japanese subjects.

Validation of the Chinese Version of Montreal Cognitive Assessment Basic for Screening Mild Cognitive Impairment

To evaluate the effectiveness of the Chinese version of the Montreal Cognitive Assessment Basic (MoCA‐BC) as a screening tool for detecting mild cognitive impairment (MCI) in Chinese elderly adults.

Comparison of the Quick Mild Cognitive Impairment (Qmci) screen to the Montreal Cognitive Assessment (MoCA) in an Australian geriatrics clinic

TLDR
This study sought to investigate how the shorter Quick Mild Cognitive Impairment (Qmci) screen compares with the MoCA.

The Montreal Cognitive Assessment and Neurobehavioral Cognitive Status Examination are useful for screening mild cognitive impairment in Japanese patients with Parkinson's disease

TLDR
The Japanese version of the Montreal Cognitive Assessment and the Neurobehavioral Cognitive Status Examination were examined whether they were suitable to screen PD‐MCI.

Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta‐analysis of diagnostic accuracy studies

TLDR
Meta‐analysis of diagnostic accuracy studies would assist clinicians in choosing optimal tests to diagnose mild cognitive impairment.
...

References

SHOWING 1-10 OF 24 REFERENCES

DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia

To design a new, highly sensitive psychometric screening to identify patients with mild cognitive impairment (MCI) and patients with dementia in the early stages of the disease.

Screening for mild cognitive impairment (MCI) utilizing combined mini‐mental‐cognitive capacity examinations for identifying dementia prodromes

To test correctness of results when combining Mini‐Mental State Examination (MMSE) and Cognitive Capacity Screening Examination (CCSE) for identifying mild cognitive impairment (MCI) among

Mild cognitive impairment

TLDR
A philosophical analysis of MCI is offered from epistemological, ethical and semantic perspectives and it is believed that the term should currently not be used clinically.

Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment.

TLDR
Compared with the MMSE, the STMS was better able to document MCI and was more sensitive in detecting deficits in cognition in individuals who had normal cognition at baseline but later developed incident MCI or Alzheimer disease.

Mild Cognitive Impairment: a Clinically Useful but Currently Ill-defined Concept?

TLDR
A brief overview discusses a number of the issues related to this topic and questions the currently accepted criteria for mild cognitive impairment.

The Mini‐Mental State Examination: A Comprehensive Review

The purpose of this paper is to provide a comprehensive review of information accumulated over the past 26 years regarding the psychometric properties and utility of the Mini‐Mental State Examination

Aging, mild cognitive impairment, and Alzheimer's disease.

Screening for dementia with the Memory Impairment Screen

TLDR
The Memory Impairment Screen provides efficient, reliable, and valid screening for AD and other dementias and presents normative data for use in settings with different base rates (prevalences) of AD and dementia.

A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease.

TLDR
The 7 Minute Screen appears highly sensitive to AD and may be useful in helping to make initial distinctions between patients experiencing cognitive changes related to the normal aging process and those experiencing cognitive deficits related to dementing disorders such as AD.